Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Dolphin Medical Services's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:526504's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.48 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Dolphin Medical Services (BOM:526504) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Dolphin Medical Services 5-Year Yield-on-Cost % Related Terms
BOM:526504 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Dolphin Medical Services's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's 5-Year Yield-on-Cost % falls into.
Dolphin Medical Services 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Dolphin Medical Services (BOM:526504) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dolphin Medical Services and its competitors. According to the industry distribution chart, Dolphin Medical Services ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry.
Is Dolphin Medical Services' 5-Year Yield-on-Cost % too high?
Dolphin Medical Services' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Dolphin Medical Services ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Dolphin Medical Services has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dolphin Medical Services ranks #999999 out of 63 companies for 5-Year Yield-on-Cost %. This places Dolphin Medical Services in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.48, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dolphin Medical Services and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dolphin Medical Services's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.39, compared to a current price of ₹7.14 — trading 198.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Dolphin Medical Services' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹7.14 is trading 198.7% above its estimated GF Value™ of ₹2.39.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹2.39 vs. price of ₹7.14 (198.7% above fair value)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
36GF Score
Get the complete analysis for BOM:526504
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
